ABG Innovation Capital Partners III GP Ltd - Q4 2020 holdings

$170 Million is the total value of ABG Innovation Capital Partners III GP Ltd's 7 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was - .

 Value Shares↓ Weighting
AVIR NewATEA PHARMACEUTICALS INC$110,265,0002,639,178
+100.0%
64.92%
LUNG NewPULMONX CORP$57,517,000833,333
+100.0%
33.86%
GNCA NewGENOCEA BIOSCIENCES INC$908,000375,000
+100.0%
0.54%
SYBX NewSYNLOGIC INC$445,000205,906
+100.0%
0.26%
ARPO NewAERPIO PHARMACEUTICALS INC$392,000400,000
+100.0%
0.23%
IDRA NewIDERA PHARMACEUTICALS INC$206,00056,250
+100.0%
0.12%
NewNABRIVA THERAPEUTICS PLC$111,00045,849
+100.0%
0.06%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

  • Fan Yu #1
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-02-16
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
SYNLOGIC INC12Q3 202333.8%
AADI BIOSCIENCES INC9Q3 202337.2%
IDERA PHARMACEUTICALS INC9Q4 20222.4%
GENOCEA BIOSCIENCES INC8Q3 202232.1%
NABRIVA THERAPEUTICS PLC7Q2 20222.3%
CASTLE BIOSCIENCES INC6Q3 202377.2%
PULMONX CORP5Q4 202133.9%
AERPIO PHARMACEUTICALS INC3Q2 20212.3%
ATEA PHARMACEUTICALS INC2Q2 202191.0%
ATEA PHARMACEUTICALS INC1Q1 202180.1%

View ABG Innovation Capital Partners III GP Ltd's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-14
13F-HR2023-11-14
13F-HR2023-08-14
13F-HR2023-05-15
13F-HR2023-02-14
13F-HR2022-11-14
13F-HR2022-08-15
13F-HR2022-05-16
13F-HR2022-02-14
13F-HR2021-11-15

View ABG Innovation Capital Partners III GP Ltd's complete filings history.

Compare quarters

Export ABG Innovation Capital Partners III GP Ltd's holdings